Incretin-based therapy and Parkinson's disease risk among patients with type 2 diabetes: Retrospective cohort study and meta-analysis.
Incretin-based therapy and Parkinson's disease risk among patients with type 2 diabetes: Retrospective cohort study and meta-analysis.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Tel Aviv, IL · Author affiliation
Department of Preventive Medicine and Epidemiology, School of Public Health, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel; Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Israel. Electronic address: yaelbarer@tauex.tau.ac.il.Location evidence
Ramat Gan, IL · Author affiliation
Department of Preventive Medicine and Epidemiology, School of Public Health, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel; The Institute of Endocrinology Diabetes and Metabolism, Sheba Medical Center, Ramat Gan, Israel; Incumbent of the Hella Gertner Chair for Research in Hypertension, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel; The Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center, Ramat Gan, Israel. Electronic address: gilad.twig@gmail.com.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
INTRODUCTION: Despite the widespread adoption of incretin-based therapy (IBT) for type 2 diabetes (T2D) and weight management, its potential neuroprotective effects remain inadequately characterized. Given emerging evidence of IBT's effects on neurodegenerative pathways, determining its association with Parkinson's disease (PD) incidence could have major clinical implications. We investigated the association between IBT and PD incidence in patients with T2D. METHODS: This retrospective cohort study identified patients with T2D between January 2008 and December 2021 who were classified as users or non-users of IBT based on time-dependent exposure and were followed for incident PD until December 2022. Additionally, a systematic literature review and meta-analysis were conducted. RESULTS: We identified 86,105 patients with T2D, of those, 347 patients developed PD. IBT use was associated with a decreased risk of PD (Hazard Ratio [HR] = 0.76, 95 % Confidence Interval [CI]:0.59-0.98), but this effect did not remain significant after confounders control (HR = 0.87, 95 % CI:0.65-1.15). The meta-analysis, comprising 12 studies and 964,446 patients, including our current cohort, revealed that IBT use was associated with a 30 % lower risk of PD (RR = 0.70, 95 % CI:0.56-0.87). This effect was more pronounced in studies including younger subjects and those with shorter T2D duration at baseline. CONCLUSIONS: The current findings suggest a negative relationship between IBT and risk of PD among patients with T2D, particularly in younger age group with short duration of the disease.